Department of Neurology, The University of Texas McGovern Medical School, Houston, TX, 77030, USA.
Department of Anesthesiology, Baylor College of Medicine, Houston, TX, USA.
J Neuroinflammation. 2023 Oct 7;20(1):230. doi: 10.1186/s12974-023-02887-7.
Stroke is the most common cause of long-term disability and places a high economic burden on the global healthcare system. Functional outcomes from stroke are largely determined by the extent of ischemic injury, however, there is growing recognition that systemic inflammatory responses also contribute to outcomes. Mast cells (MCs) rapidly respond to injury and release histamine (HA), a pro-inflammatory neurotransmitter that enhances inflammation. The gut serves as a major reservoir of HA. We hypothesized that cromolyn, a mast cell stabilizer that prevents the release of inflammatory mediators, would decrease peripheral and central inflammation, reduce MC trafficking to the brain, and improve stroke outcomes. We used the transient middle cerebral artery occlusion (MCAO) model of ischemic stroke in aged (18 mo) male mice to investigate the role of MC in neuroinflammation post-stroke. After MCAO we treated mice with 25 mg/kg body weight of cromolyn (MC stabilizer) by oral gavage. Cromolyn was administered at 3 h, 10 h, 24 h and every 24 h for 3 days post-stroke. Three control groups were used. One group underwent a sham surgery and was treated with cromolyn, one received sham surgery with PBS vehicle and the third underwent MCAO with PBS vehicle. Mice were euthanized at 24 h and 3 days post-stroke. Cromolyn administration significantly reduced MC numbers in the brain at both 24 h and 3 days post-stroke. Infarct volume was not significantly different between groups, however improved functional outcomes were seen at 3 days post-stroke in mice that received cromolyn. Treatment with cromolyn reduced plasma histamine and IL-6 levels in both the 24-h and 3-day cohorts. Gut MCs numbers were significantly reduced after cromolyn treatment at 24 h and 3 days after stroke. To determine if MC trafficking from the gut to the brain occurred after injury, GFPMCs were adoptively transferred to c-kit MC knock-out animals prior to MCAO. 24 h after stroke, elevated MC recruitment was seen in the ischemic brain. Preventing MC histamine release by cromolyn improved gut barrier integrity and an improvement in stroke-induced dysbiosis was seen with treatment. Our results show that preventing MC histamine release possesses prevents post-stroke neuroinflammation and improves neurological and functional outcomes.
中风是长期残疾的最常见原因,给全球医疗保健系统带来了沉重的经济负担。中风的功能结果在很大程度上取决于缺血性损伤的程度,然而,人们越来越认识到,全身炎症反应也会影响结果。肥大细胞(MC)对损伤迅速做出反应并释放组织胺(HA),HA 是一种促炎神经递质,可增强炎症反应。肠道是 HA 的主要储存库。我们假设肥大细胞稳定剂色甘酸钠可防止炎症介质的释放,从而减少外周和中枢炎症、减少 MC 向大脑的迁移,并改善中风结果。我们使用了年龄较大(18 个月)雄性小鼠的短暂性大脑中动脉闭塞(MCAO)模型来研究 MC 在中风后神经炎症中的作用。在 MCAO 后,我们通过口服灌胃给予小鼠 25mg/kg 体重的色甘酸钠(MC 稳定剂)。色甘酸钠在中风后 3 小时、10 小时、24 小时和 3 天每 24 小时给药一次。使用了三组对照。一组接受假手术并给予色甘酸钠,一组接受假手术和 PBS 载体,第三组接受 MCAO 和 PBS 载体。在中风后 24 小时和 3 天时处死小鼠。色甘酸钠给药显著减少了中风后 24 小时和 3 天时大脑中的 MC 数量。各组之间的梗死体积没有显著差异,但在接受色甘酸钠治疗的小鼠中,在中风后 3 天观察到了功能结果的改善。色甘酸钠治疗降低了两组中风后 24 小时和 3 天的血浆组织胺和 IL-6 水平。中风后 24 小时和 3 天时,色甘酸钠治疗后肠道 MC 数量明显减少。为了确定是否发生了从肠道到大脑的 MC 迁移,在 MCAO 之前将 GFP-MCs 过继转移到 c-kit MC 敲除动物体内。中风后 24 小时,在缺血性大脑中观察到 MC 募集增加。用色甘酸钠阻止 MC 释放组胺可改善肠道屏障完整性,并观察到治疗后中风诱导的肠道菌群失调得到改善。我们的结果表明,阻止 MC 释放组胺可预防中风后的神经炎症,并改善神经和功能结果。